Advertisement

Liposomes in Antimicrobial Therapy

  • Gabriel Lopez-Berestein
  • Rudolph L. Juliano
  • Kapil Mehta
  • Reeta Mehta
  • Teresa McQueen
  • Roy L. Hopfer
Part of the NATO ASI Series book series (NSSA, volume 113)

Abstract

The development of new therapeutic modalities involves the synthesis of new drugs or drug analogues, or a modification of the therapeutic index of established active drugs. The latter can be accomplished by the use of drug carriers, such as liposomes, which can modify the pharmacokinetics and distribution of drugs.

Keywords

Fungal Infection Visceral Leishmaniasis Cutaneous Leishmaniasis Hairy Cell Leukemia Systemic Fungal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P.F. Bonventre and G. Gregoriadis, Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped within liposomes, Antimicrob. Agents Chemother. 13:1049 (1978).CrossRefGoogle Scholar
  2. 2.
    R.R.C. New, M.L. Chance, S.C. Thomas and W. Peters, Antileishmanial activity of antimonials entrapped in liposomes, Nature 272:55 (1978).CrossRefGoogle Scholar
  3. 3.
    C.R. Alving, E.A. Steck, W.L. Hanson, P.S. Loizeauz, W.L. Chapman, Jr. and V.B. Waits, Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug, Life Sci. 22:1021 (1978).CrossRefGoogle Scholar
  4. 4.
    R.R.C. New and M.L. Chance, Treatment of experimental cutaneous leishmaniasis by liposome-entrapped Pentostam, Acta. Trop. 37:253 (1980).Google Scholar
  5. 5.
    J.V. Desiderio and S.G. Campbell, Intraphagocytic killing of salmonella typhimurium by liposome-encapsulated cephalothin, J. Infect. Pis. 148:563 (1983).CrossRefGoogle Scholar
  6. 6.
    J.V. Desiderio and S.G. Campbell, Liposome-encapsulated cephalothin in the treatment of experimental murine salmonellosis, J. Reticulo-endothel. Soc. 34:279 (1983).Google Scholar
  7. 7.
    C.R. Alving, Delivery of liposome-encapsulated drugs to macrophages, Pharmacol. Ther. 22:407 (1983).CrossRefGoogle Scholar
  8. 8.
    J.S. Weldon, J.F. Munnell, W.L. Hanson and C.R. Alving, Liposomal chemotherapy in visceral leishmaniasis: An ultrastructural study of an intracellular pathway, Z. Parasitenkd. 69:415 (1983).CrossRefGoogle Scholar
  9. 9.
    C.R. Alving, G.M. Swartz, Jr., L.D. Hendricks, W.L. Chapman, Jr., V.B. Waits and W.L. Hanson, Liposomes in leishmaniasis: Effects of parasite virulence on treatment of experimental leishmaniasis in hamsters, Ann. Trop. Med. Parasitol. 78:279 (1984).Google Scholar
  10. 10.
    W.L. Chapman, Jr., W.L. Hanson, C.R. Alving and L.D. Hendricks, Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog, Am. J. Vet. Res. 45:1028 (1984).Google Scholar
  11. 11.
    R.R.C. New, M.L. Chance and S. Heath, Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes, J. Antimicrob. Chemother. 8:371 (1981).CrossRefGoogle Scholar
  12. 12.
    C.B. Panosian, M. Barza, F. Szoka and D.J. Wyler, Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B, Antimicrob. Agents Chemother. 25:655 (1984).CrossRefGoogle Scholar
  13. 13.
    S.G. Reed, M. Barral-Netto and J.A. Inverso, Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes, J. Immunol. 132:3116 (1984).Google Scholar
  14. 14.
    P. Pirson, R.F. Steiger, A. Trouet, J. Gillet and F. Herman, Primaquine liposomes in the chemotherapy of experimental murine malaria, Ann. Trop. Med. Parasitol. 74:383 (1980).Google Scholar
  15. 15.
    J.E. Smith and R.E. Sinden, Studies on the kinetics of uptake and distribution of free and liposome-entrapped primaquine and of spor-ozoites by isolated perfused rat liver, Ann. Trop. Med. Parasitol. 77:379 (1983).Google Scholar
  16. 16.
    P. Pirson, R. Steiger and A. Trouet, The disposition of free and liposomally encapsulated antimalarial primaquine in mice, Biochem. Pharmacol. 31:3501 (1982).CrossRefGoogle Scholar
  17. 17.
    G.P. Bodey, V. Rodriguez, H.-Y. Chang and G. Narboni, Fever and infection in leukemic patients. A study of 494 consecutive patients, Cancer 41:1610 (1978).CrossRefGoogle Scholar
  18. 18.
    L.S. Young, Nosocomial infections in the immunocompromised adult, Am. J. Med. 70:398 (1981).CrossRefGoogle Scholar
  19. 19.
    R.L. Taylor, D.M. Williams, P.C. Draven, J.R. Graybill, D.J. Drutz and W.E. Magee, Amphotericin B in liposomes: A novel therapy for histoplasmosis, Am. Rev. Respir. Dis. 125:610 (1981).Google Scholar
  20. 20.
    J.R. Graybill, P.C. Carven, R.L. Taylor, D.M. Williams and W.E. Magee, Treatment of murine cryptococcosis with liposome-associated ampho B, J. Infect. Dis. 145:748 (1982).CrossRefGoogle Scholar
  21. 21.
    J. Ahrens, J.R. Graybill, P.C. Carven and R.L. Taylor, Treatment of experimental murine candidiasis with liposome-associated amphotericin B, Sabouraudia: J. Med. Vet. Mycol. 22:163 (1984).CrossRefGoogle Scholar
  22. 22.
    C. Tremblay, M. Barza, C. Fiore and F. Szoka, Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice, Antimicrob. Agents Chemother. 26:170 (1984).CrossRefGoogle Scholar
  23. 23.
    G. Lopez-Berestein, T. McQueen and K. Mehta, Protective effect of liposomal-amphotericin B against C. albicans in mice, Cancer Drug Delivery, In press.Google Scholar
  24. 24.
    G. Lopez-Berestein, R.L. Hopfer, R. Mehta, E.M. Hersh and R.L. Juliano, Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice, J. Infect. Dis. 150:278 (1984).CrossRefGoogle Scholar
  25. 25.
    R.L. Hopfer, K. Mills, R. Mehta, G. Lopez-Berestein, V. Fainstein and R. L. Juliano, In-vitro antifungal activities of amphotericin and liposome-encapsulated amphotericin B, Antimicrob. Agents Chemother. 25:387 (1984).CrossRefGoogle Scholar
  26. 26.
    G. Lopez-Berestein, R. Mehta, R. Hopfer, K. Mehta, E.M. Hersh and R. Juliano, Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis, Cancer Prug Peliv. 1:37 (1983).CrossRefGoogle Scholar
  27. 27.
    R. Mehta, G. Lopez-Berestein, R. Hopfer, K. Mills and R.L. Juliano, Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells, Biochim. Biophys. Acta 770:230 (1984).CrossRefGoogle Scholar
  28. 28.
    B.D. Fisher, P. Armstrong, B. Yu and J.W.M. Gold, Invasive aspergillosis. Progress in early diagnosis and treatment, Am. J. Med. 71:571 (1981).CrossRefGoogle Scholar
  29. 29.
    M.W. Pegregorio, W.M. Lee, C.A. Linker, R.J. Jacobs and CA. Ries, Fungal infections in patients with acute leukemia, Am. J. Med. 73: 543 (1982).CrossRefGoogle Scholar
  30. 30.
    H.S. Mirsky and J. Cuttner, Fungal infection in acute leukemia, Cancer 30:348 (1972).CrossRefGoogle Scholar
  31. 31.
    R.L. Myerowitz, G.J. Pazin and C.M. Allen, Disseminated candidiasis. Changes in incidence, underlying disease, and pathology, Am. J. Clin. Pathol. 68:29 (1977).Google Scholar
  32. 32.
    L.P. Kasi, G. Lopez-Berestein, K. Mehta, M. Rosenblum, H.J. Glenn, T.P. Haynie, G. Mavligit and E.M. Hersh, Distribution and pharmacology of intravenous 99mTc-labeled multilamellar liposomes in rats and mice, Int. J. Nucl. Med. Biol. 2:35 (1984).CrossRefGoogle Scholar
  33. 33.
    G. Lopez-Berestein, L. Kasi, M.G. Rosenblum, T. Haynie, M. Jahns, H. Glenn, R. Mehta, G.M. Mavligit and E.M. Hersh, Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer, Cancer Res. 44:375 (1984).Google Scholar
  34. 34.
    G. Lopez-Berestein, M.G. Rosenblum and R. Mehta, Altered tissue distribution of amphotericin B by liposomal encapsulation: Comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv. 1:199 (1984).CrossRefGoogle Scholar
  35. 35.
    G. Lopez-Berestein, R. Mehta, R.L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E.M. Hersh and R. Juliano, Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B, J. Infect. Dis. 147:939 (1983).CrossRefGoogle Scholar
  36. 36.
    G. Lopez-Berestein, V. Fainstein, R. Hopfer, K. Mehta, M.P. Sullivan, M. Keating, M.G. Rosenblum, R. Mehta, M. Luna, E.M. Hersh, J. Reuben, R.L. Juliano and G.P. Bodey, Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study, J. Infect. Dis. 151:704 (1985).CrossRefGoogle Scholar
  37. 37.
    G. Lopez-Berestein, K. Mehta, R. Mehta, R.L. Juliano and E.M. Hersh, The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues, J. Immunol. 130:1500 (1983).Google Scholar
  38. 38.
    K. Mehta, G. Lopez-Berestein, E.M. Hersh and R.L. Juliano, Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes, J. Reticuloendothel. Soc. 32:155 (1982).Google Scholar
  39. 39.
    K. Mehta, R.L. Juliano and G. Lopez-Berestein, Stimulation of macrophage protease secretion via liposomal delivery of muramyl dipeptide derivatives to intracellular sites, Immunol. 51:517 (1984).Google Scholar
  40. 40.
    G. Lopez-Berestein, L. Milas, N. Hunter, K. Mehta, E.M. Hersh, C.G. Kurahara, M. VanderPas and D.A. Eppstein, Prophylasis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6–0-stearoyl-N-acetylmuramyl-l-alpha-amino-butyryl-d-isoglutamine, Clin. Expl. Metastasis 2:127 (1984).CrossRefGoogle Scholar
  41. 41.
    W.C. Koff, I.J. Fidler, S.D. Showalter, M.K. Chakrabarty, B. Hampar, L.M. Ceccorulli and E.S. Kleinerman, Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells, Science 224:1007 (1984).CrossRefGoogle Scholar
  42. 42.
    LaBonnardiere C. Donnees preliminaires sur l’effet protecteur de l’interferon couple a des liposomes dans le modele souris-virus de l’hepatite murine, Ann. Microbiol. 129:397 (1978).Google Scholar
  43. 43.
    W.C. Koff, Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide, Science 228: 495 (1985).CrossRefGoogle Scholar
  44. 44.
    W.C. Koff, S.D. Showalter, D.A. Seniff and B. Hampar, Lysis of herpes-virus-infected cells by macrophages activated with free or liposome-encapsulated lymphokine produced by a murine T cell hybridoma, Infect. Immun. 42:1067 (1983).Google Scholar
  45. 45.
    E.B. Fraser-Smith, D.A. Eppstein, M.A. Larsen and T.R. Matthews, Protective effect of a muramyl dipeptide analog encapsulated in or mixed with liposomes against Candida albicans infection, Infect. Immun. 39:172 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Gabriel Lopez-Berestein
    • 1
  • Rudolph L. Juliano
    • 3
  • Kapil Mehta
    • 1
  • Reeta Mehta
    • 3
  • Teresa McQueen
    • 1
  • Roy L. Hopfer
    • 2
  1. 1.Department of Clinical Immunology and Biological TherapyThe University of Texas M.D. Anderson Hospital and Tumor Institute at HoustonHoustonUSA
  2. 2.Laboratory MedicineThe University of Texas M.D. Anderson Hospital and Tumor Institute at HoustonHoustonUSA
  3. 3.Department of PharmacologyThe University of Texas Medical School at HoustonHoustonUSA

Personalised recommendations